Phaseline

Targets › DRD5

DRD5 (Dopamine receptor D5): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology, Neurology; next expected readout Jan 2027.

G protein-coupled receptor for dopamine, a catecholamine neurotransmitter hormone that functions as the brain's 'reward chemical', driving motivation, reinforcement learning and pleasure. Dopamine binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. (UniProt, P21918)

Open in Phaseline: the race on DRD5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Serina TherapeuticsSER-252 (PEOZ-apomorphine)
Dopamine receptor agonist (D1-like and D2-like dopamine receptors)
DRD1, DRD2, DRD3, DRD4, DRD5Phase 1PARKINSON DISEASE (Disorder)Jan 2027
National Cancer Institute (NCI)ONC201 (Dordaviprone Hydrochloride)
Dopamine receptor antagonist; induces cancer cell death through SLC7A11 inhibition and fer
DRD5Phase 1Colorectal Adenomatous PolypJul 2028

Conditions

Colorectal Adenomatous Polyp (1) PARKINSON DISEASE (Disorder) (1)

Modalities

small molecule (2)

Companies

National Cancer Institute (NCI) (1) Serina Therapeutics (1)

Related targets

DRD1 (1) DRD2 (1) DRD3 (1) DRD4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.